Corcept Therapeutics (CORT) Income towards Parent Company (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Income towards Parent Company data on file, last reported at -$31.7 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 254.57% year-over-year to -$31.7 million; the trailing twelve-month figure through Mar 2026 stood at $47.4 million (down 64.63% YoY), and the FY2025 full-year result was $99.7 million, down 29.43% from the prior year.
• Income towards Parent Company eased to -$31.7 million in Q1 2026, from $24.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $47.2 million in Q3 2024 to a low of -$31.7 million in Q1 2026.
• A 5-year average of $24.5 million and a median of $27.5 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company jumped 89.07% in 2023 and sank 254.57% in 2026, its largest moves.
• Tracing CORT's Income towards Parent Company over 5 years: stood at $16.6 million in 2022, then surged by 89.07% to $31.4 million in 2023, then fell by 2.06% to $30.7 million in 2024, then slipped by 20.97% to $24.3 million in 2025, then sank by 230.52% to -$31.7 million in 2026.
• Business Quant data shows CORT's Income towards Parent Company at -$31.7 million in Q1 2026, $24.3 million in Q4 2025, and $19.7 million in Q3 2025.